Navigation Links
More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
Date:4/23/2008

MONROVIA, Calif., April 23 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced very strong participation in the first of its nine-part webinar series on the Company's Visian ICL(TM) (Implantable Collamer Lens). The first session which aired Tuesday, April 22, 2008, titled "How My Website Compels Patients to Call Me," is part of a new marketing initiative designed to help refractive physicians build their Visian ICL practices. Over 450 physicians and more than 250 practice administrators registered for the ICL Growth Program.

The ICL Growth Program, developed in collaboration with Dr. Brian Boxer Wachler, focuses on the key elements required to build a successful Visian ICL practice. Dr. Boxer Wachler has developed a thriving Visian ICL practice and was recently featured on the NBC News Today show performing bilateral implants of the Visian ICL in his office suite. In addition, the work of other Visian ICL surgeons has been featured on numerous shows recently, including Dr. Steven Chang on ABC News in San Francisco, Dr. Konrad Filutowski on Fox News in Orlando and Dr. William Goldstein on Fox News in Detroit, while Dr. Paul Dougherty will be featured on an episode of the "Modern Beauty Show" airing on the Style Channel in three parts this month.

"We are pleased and excited that so many physicians and practice administrators took advantage of this program," said Barry G. Caldwell, President and CEO of STAAR. "Our ICL Growth Program is designed to help interested surgeons capitalize on the growing consumer awareness of the Visian ICL's benefits and complements our recent growth curve in the U.S. market. Dr. Boxer Wachler has made the Visian ICL an integral part of his successful practice, and we are delighted to have him share his story with other physicians. In future sessions of this nine part series other successful surgeons may be joining Dr. Boxer Wachler to share their experiences."

About STAAR Surgical

STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More information is available at http://www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of managing foreign subsidiaries, the willingness of surgeons and patients to adopt a new product and procedure and other factors beyond our control, including those detailed from time to time in our reports filed with the Securities and Exchange Commission. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

Contacts: Investors Media

EVC Group EVC Group

Doug Sherk, 415-896-6820 Steve DiMattia, 646-277-8706

Matthew Selinger, 415-896-6817 Chris Gale, 646-201-5431


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
3. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
4. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
7. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
8. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition
9. Off-Label Stent Use: How Important Are FDA Approvals to Physicians?
10. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):